MedTrace Logo

Rebalancing the Fat Content of the Heart and Muscles

NCT07065383 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-04-30

No results posted yet for this study

Summary

Traditional diabetes therapies focus on improving blood sugar control. However, many studies show that this may not be enough. New treatments focusing on weight loss have heralded better results. One of these treatments is Semaglutide and the investigators wish to examine its effects further in this study. The investigators propose to investigate what happens to the fat inside the heart and the leg muscles.

Conditions

  • Diabetes Mellitus Type 2

Interventions

DRUG

Semaglutide administration plus dietary counselling and physical activity encouragement

Semaglutide administration plus dietary counselling and physical activity encouragement

DRUG

Semaglutide plus a personalised and supervised program of resistance and endurance training

Semaglutide administration plus a personalised and supervised program of resistance and endurance training.

Sponsors & Collaborators

  • NHS Grampian

    collaborator OTHER_GOV

  • University of Aberdeen

    lead OTHER

Principal Investigators

  • Dana Dawson, DM · University of Aberdeen

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-01
Primary Completion
2028-07-31
Completion
2028-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07065383 on ClinicalTrials.gov